Garetosmab

Garetosmab (REGN2477) Research Guide

What is Garetosmab?

Garetosmab is a fully human IgG4 monoclonal antibody that binds and neutralises activin A. Its development code is REGN2477. It was generated by Regeneron on the VelocImmune platform, the same fully-human-antibody platform behind [Trevogrumab](/product/trevogrumab).

Key identifiers: CAS 2097125-54-5, approximately 145.5 kDa, IgG4 isotype. Expressed in Chinese hamster ovary cells and purified by Protein A affinity chromatography.

Garetosmab is not a peptide. It is a four-chain immunoglobulin, two heavy and two light chains, disulfide-linked and N-glycosylated. Peptide synthesis cannot produce it and a peptide certificate cannot characterise it.

How does Garetosmab work?

Activin A is a TGF-beta superfamily ligand, a homodimer of two inhibin beta-A subunits. It signals through the activin type II receptors ActRIIA and ActRIIB paired with ALK4, driving SMAD2 and SMAD3 phosphorylation.

Garetosmab is a ligand trap: it binds activin A and blocks receptor engagement.

What makes it useful is the precision of that binding. Garetosmab binds and inhibits activins containing the inhibin beta-A subunit, meaning activin A, activin AB and activin AC. It does not bind or functionally inhibit:

• activin B
• inhibin A
• BMP-2, BMP-6, BMP-9, BMP-10
• GDF8 (myostatin)
• GDF11

Why is activin A selectivity hard, and why does it matter?

The TGF-beta superfamily is a crowded receptor space. Activin A, activin B, myostatin, GDF11 and several BMPs converge on a small set of shared type I and type II receptors and feed the same SMAD transcriptional machinery. A tool that binds four of them produces a phenotype no downstream assay can decompose.

Garetosmab draws its line at the ligand rather than the receptor. Anything it does in a model can be attributed to activin A, AB or AC and to nothing else on that list. For designs that must separate activin signalling from BMP signalling in the same tissue, that specificity is the whole value of the reagent.

What is the FOP and ACVR1 research context?

Regeneron scientists identified activin A as the driver of heterotopic ossification in fibrodysplasia ossificans progressiva (FOP), an ultra-rare condition in which the mutant ACVR1 receptor misreads activin A as an osteogenic signal. In healthy tissue activin A does not drive bone formation; in FOP the mutant receptor converts it into a bone-forming input.

In the reported Phase 2 study:

| Dose | Reduction in new heterotopic ossification lesions | p-value | | --- | --- | --- | | 3 mg/kg | 94% (1 lesion vs 19 on placebo) | 0.0274 | | 10 mg/kg | 90% (2 lesions vs 19 on placebo) | 0.0260 |

The FDA granted Fast Track designation in 2017 and accepted the Biologics License Application for Priority Review, with a target action date in August 2026. As of writing, garetosmab is investigational and is not an approved medicine in any jurisdiction. Material supplied here is a research reagent, unrelated to any clinical supply chain.

What did COURAGE show about garetosmab, including tolerability?

Garetosmab was the third agent in Regeneron's Phase 2 COURAGE obesity trial (NCT06299098), added on top of semaglutide and [Trevogrumab](/product/trevogrumab). Results were presented at EASD 2025.

Change in lean body mass from baseline at 26 weeks:

| Arm | Lean body mass change | | --- | --- | | Semaglutide alone | -6.5% | | Semaglutide + trevogrumab 200 mg | -3.3% | | Semaglutide + trevogrumab 400 mg | -3.8% | | Semaglutide + trevogrumab + garetosmab | -2.0% |

The triplet reached 80.9 percent lean mass preservation and a 27.3 percent increase in fat mass reduction versus semaglutide alone, the strongest body-composition result in the study.

It also carried the worst tolerability. Semaglutide plus trevogrumab was generally well tolerated, but the triplet had a substantially higher rate of discontinuations for tolerability and other adverse events. Adverse events reported in at least 5 percent of any group included muscle spasms, nausea, constipation, fatigue, diarrhoea, headache, vomiting, gastro-oesophageal reflux, upper respiratory tract infection, nasopharyngitis, urinary tract infection, influenza and COVID-19.

That trade-off, the best body composition and the worst discontinuation rate in the same arm, is the single most useful thing to know about this compound, and it is why activin A blockade is studied as an addition rather than a default.

Research applications

• Activin A pathway pharmacology and ligand-selective neutralisation
• SMAD2 and SMAD3 signalling studies requiring separation of activin from BMP inputs
• ACVR1 and heterotopic ossification research models
• Muscle and metabolic research, where activin A is a second ActRII ligand alongside myostatin
• Paired studies with [Trevogrumab](/product/trevogrumab) to dissect activin A and myostatin contributions in one model
• Comparative work against non-selective approaches such as follistatin or soluble ActRIIB-Fc decoys, which bind activin A and myostatin both and cannot separate the two
• Antibody handling, formulation and stability method development

Why run Garetosmab and Trevogrumab together?

Myostatin and activin A are the two principal ActRII ligands restraining skeletal muscle mass, and they signal through overlapping receptors into the same SMAD pathway. Blocking one leaves the other intact, which is why single-ligand results in this space are frequently smaller than receptor-level blockade predicts.

COURAGE is the clearest demonstration: trevogrumab alone took lean mass loss from -6.5% to -3.3%, and adding garetosmab took it to -2.0%. Running both antibodies alone and in combination is the standard design for apportioning an ActRII-blockade phenotype between the two ligands. Since neither antibody cross-reacts with the other's target, the combination is genuinely additive rather than confounded.

For how both compare against the receptor-level and pro-form-selective approaches, see the [myostatin inhibitor comparison guide](/blog/trevogrumab-vs-garetosmab-vs-bimagrumab-vs-apitegromab).

How is an antibody tested differently from a peptide?

A peptide certificate reports reversed-phase HPLC purity, an ESI-MS charge state and Karl Fischer water. For a 145 kDa glycoprotein none of those are the right measurement: reversed-phase conditions denature the molecule, a single-charge-state mass is meaningless against a glycan-heterogeneous population, and the impurities that matter are not synthesis by-products.

The antibody panel:

| Attribute | Method | Why it exists | | --- | --- | --- | | Monomer purity | SEC-HPLC | Aggregation is the primary quality risk | | Aggregate content | SEC-HPLC | Quantified separately from the monomer peak | | Identity and chain integrity | SDS-PAGE, reduced and non-reduced | ~150 kDa intact; ~50 and ~25 kDa on reduction | | Identity | Deglycosylated intact mass | The mass check that works on a glycosylated protein | | Binding activity | ELISA against immobilised activin A | Pure but inactive is a failed lot | | Selectivity | Counter-screen across the ligand family | The property the compound is bought for | | Endotoxin | LAL | Mammalian cell culture product | | Concentration | UV A280 | Reported, not assumed |

Handling and storage

• Lyophilized, unopened: 2 to 8 degrees Celsius, 24 months
• Reconstitute gently: diluent down the vial wall, swirl, never vortex or shake
• Reconstituted: 2 to 8 degrees Celsius up to 4 weeks, or single-use aliquots at minus 80 degrees Celsius
• Aliquot before freezing: freeze-thaw cycling is the dominant aggregation driver
• Avoid foaming and unnecessary transfers: the air-liquid interface denatures antibody

Quality standards

• Monomer purity: 98 percent or greater by SEC-HPLC, aggregates reported separately
• Expression system: CHO mammalian cell culture, Protein A purified
• Endotoxin: less than 1.0 EU/mg by LAL
• Form: lyophilized from a histidine and sucrose matrix in single-use vials
• Documentation: batch-matched antibody Certificate of Analysis published at /lab-results
• Fill strengths: 0.1 mg, 1 mg, 5 mg, 10 mg and 100 mg, priced per vial

For laboratory research purposes only. Not for human consumption, therapeutic use, or any in vivo application in humans. Garetosmab is an investigational compound and is not approved as a medicine in any jurisdiction.